RecruitingNCT03418350
The Role of Laryngopharyngeal Reflux in IPF
Sponsor
National Jewish Health
Enrollment
60 participants
Start Date
Aug 1, 2018
Study Type
OBSERVATIONAL
Conditions
Summary
The primary objective of this study is to show that the Supraglottic Index (SGI) is an easily-collected index that accurately identifies the presence and severity of laryngopharyngeal reflux (LPF) in idiopathic pulmonary fibrosis (IPF).
Eligibility
Min Age: 40 YearsMax Age: 95 Years
Inclusion Criteria5
- Diagnosis of IPF
- Age 40-95
- Able to read, speak, and understand English
- If subjects are currently taking medication for reflux or GERD, they much be on a stable does for at least 4 weeks prior to consent.
- Pregnant females
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03418350
Related Trials
A Phase Ia Clinical Trial of HW241045
NCT074481941 location
Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF
NCT061813701 location
Telerehabilitation in Patients With Idiopathic Pulmonary Fibrosis
NCT051902111 location
SB17170 Phase 2 Trial in IPF Patients
NCT067479235 locations
Turkish Validity and Reliability of SGRQ-I
NCT051475971 location